Therefore, further exploring novel therapeutic targets for HER2+ breast cancer and delineating the mechanisms associated with resistance to anti-HER2 agents could improve the treatment of HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.